← Back to Screener
OS Therapies Incorporated (OSTX)
Price$1.78
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-8.48%
Price vs S&P 500 (4W)7.24%
VGM Score57.38
Market Capitalization$79.28M
All Metrics
Book Value / Share (Quarterly)$0.14
Cash Flow / Share (Quarterly)$-0.40
Price vs S&P 500 (YTD)18.99%
EPS (TTM)$-1.05
10-Day Avg Trading Volume0.90M
EPS Excl Extra (TTM)$-1.05
EPS (Annual)$-0.98
ROI (Annual)-1094.65%
Cash / Share (Quarterly)$0.02
ROA (Last FY)-420.41%
EBITD / Share (TTM)$-1.02
Cash Flow / Share (Annual)$-0.40
P/B Ratio16.84x
P/B Ratio (Quarterly)13.96x
Net Income / Employee (Annual)$-7,188,500
Net Interest Coverage (TTM)-3.33x
ROA (TTM)-422.41%
EPS Incl Extra (Annual)$-0.98
Current Ratio (Annual)0.03x
Quick Ratio (Quarterly)0.05x
3-Month Avg Trading Volume0.66M
52-Week Price Return9.20%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.02
52-Week High$2.57
EPS Excl Extra (Annual)$-0.98
26-Week Price Return-0.56%
Quick Ratio (Annual)0.02x
13-Week Price Return17.88%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.05x
Enterprise Value$79.70M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.01
3-Month Return Std Dev82.00%
Net Income / Employee (TTM)$-8,818,500
ROE (Last FY)-1094.65%
Net Interest Coverage (Annual)-137.09x
EPS Basic Excl Extra (Annual)$-0.98
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.05
ROI (TTM)-567.59%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-15.16%
Year-to-Date Return27.14%
5-Day Price Return-4.81%
EPS Normalized (Annual)$-0.98
ROA (5Y Avg)-1012.51%
Month-to-Date Return-16.82%
EBITD / Share (Annual)$-0.97
EPS Basic Excl Extra (TTM)$-1.05
P/TBV (Quarterly)71.95x
P/B Ratio (Annual)112.02x
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)9.63%
Beta1.05x
Revenue / Share (TTM)$0.00
ROE (TTM)-567.59%
52-Week Low$1.15
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.27est. -0.18
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OSTXOS Therapies Incorporated | — | — | C | $1.78 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
OS Therapies is a clinical-stage biopharmaceutical company developing treatments for osteosarcoma and other solid tumors in children and young adults. The company addresses an unmet medical need in pediatric and adolescent bone cancer therapeutics.